Cite

HARVARD Citation

    Castroviejo‐Bermejo, M. et al. (2018). A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO molecular medicine. 10 (12), p. n/a. [Online]. 
  
Back to record